|
84 Companies |
|
139 Products |
|
139 Products |
|
62 Mechanisms of Action |
|
7 Trials |
|
632 News |
|
| «12...234567891011121314» |
- Neupogen (filgrastim) / Kyowa Kirin, Amgen
Clinical: Donor Umbilical Cord Blood Transplant in Treating Patients With Hematologic Cancer (clinicaltrials.gov) - Oct 8, 2012
P=N/A, N=43, Terminated, Sponsor: Masonic Cancer Center, University of Minnesota
N=60 --> 43
- Neupogen (filgrastim) / Kyowa Kirin, Amgen
Trial withdrawal: Peripheral Stem Cell Transplantation With Specially Treated Stem Cells in Treating Patients With Non-Hodgkin's Lymphoma or Hodgkin's Disease (clinicaltrials.gov) - Oct 8, 2012
P2, N=0, Withdrawn, Sponsor: Masonic Cancer Center, University of Minnesota
N=60 --> 43 Terminated --> Withdrawn
- Enrollment change, Metastases: Combination Chemotherapy and Total-Body Irradiation Before Donor Umbilical Cord Blood Transplant in Treating Patients With Advanced Hematologic Cancer, Metastatic Breast Cancer, or Kidney Cancer (clinicaltrials.gov) - Oct 8, 2012
P1/2, N=148, Completed, Sponsor: Masonic Cancer Center, University of Minnesota
Terminated --> Withdrawn N=120 --> 148
- Trial completion, Metastases: Combination Chemotherapy and Total-Body Irradiation Before Donor Umbilical Cord Blood Transplant in Treating Patients With Advanced Hematologic Cancer, Metastatic Breast Cancer, or Kidney Cancer (clinicaltrials.gov) - Oct 8, 2012
P1/2, N=148, Completed, Sponsor: Masonic Cancer Center, University of Minnesota
N=120 --> 148 Terminated --> Completed
- Trial completion: Chemotherapy and Total-Body Irradiation Followed by Donor Umbilical Cord Blood Transplant, Cyclosporine, and Mycophenolate Mofetil in Treating Patients With Hematologic Cancer (clinicaltrials.gov) - Oct 8, 2012
P=N/A, N=68, Completed, Sponsor: Masonic Cancer Center, University of Minnesota
Terminated --> Completed Terminated --> Completed
- human allogeneic myeloid progenitor cells (CLT-008) / Cellerant Therap
Enrollment change, Post-transplantation: Safety Study of Human Myeloid Progenitor Cells (CLT-008) After Cord Blood Transplant for Hematologic Malignancy (clinicaltrials.gov) - Oct 4, 2012
P1, N=40, Recruiting, Sponsor: Cellerant Therapeutics
Terminated --> Completed N=22 --> 40
- Epogen (epoetin alfa) / Amgen
Enrollment change: Epoetin Alfa in Treating Patients With Anemia Who Are Undergoing Chemotherapy for Cancer (clinicaltrials.gov) - Oct 2, 2012
P2, N=89, Completed, Sponsor: Jonsson Comprehensive Cancer Center
N=22 --> 40 N=180 --> 89
- Epogen (epoetin alfa) / Amgen
Trial completion: Epoetin Alfa in Treating Patients With Anemia Who Are Undergoing Chemotherapy for Cancer (clinicaltrials.gov) - Oct 2, 2012
P2, N=89, Completed, Sponsor: Jonsson Comprehensive Cancer Center
N=180 --> 89 Active, not recruiting --> Completed
- Trial completion: Donor Stem Cell Transplant in Treating Older or Frail Patients With Hematologic Cancer (clinicaltrials.gov) - Oct 1, 2012
P=N/A, N=25, Completed, Sponsor: University of California, San Francisco
Active, not recruiting --> Completed Active, not recruiting --> Completed
- fludarabine IV / Generic mfg., busulfan / Generic mfg.
Enrollment change: Busulfan and Fludarabine Before Donor Stem Cell Transplant in Treating Patients With Hematologic Cancer (clinicaltrials.gov) - Sep 30, 2012
P2, N=0, Withdrawn, Sponsor: University of California, San Francisco
Active, not recruiting --> Completed N=36 --> 0
- ciprofloxacin oral / Generic mfg., amoxycillin/clavulanate / Generic mfg.
Trial termination, Combination therapy, Monotherapy: Moxifloxacin Compared With Ciprofloxacin/Amoxicillin in Treating Fever and Neutropenia in Patients With Cancer (clinicaltrials.gov) - Sep 19, 2012
P=N/A, N=351, Terminated, Sponsor: European Organisation for Research and Treatment of Cancer - EORTC
N=36 --> 0 Active, not recruiting --> Terminated; low accrual
- ciprofloxacin oral / Generic mfg., amoxycillin/clavulanate / Generic mfg.
Enrollment change, Combination therapy, Monotherapy: Moxifloxacin Compared With Ciprofloxacin/Amoxicillin in Treating Fever and Neutropenia in Patients With Cancer (clinicaltrials.gov) - Sep 19, 2012
P=N/A, N=351, Terminated, Sponsor: European Organisation for Research and Treatment of Cancer - EORTC
Active, not recruiting --> Terminated; low accrual N=530 --> 351
- | amphotericin b liposome / Generic mfg.
Enrollment change: Liposomal Amphotericin B in Treating Granulocytopenia and Persistent Unexplained Fever in Cancer Patients (clinicaltrials.gov) - Sep 19, 2012
P3, N=115, Completed, Sponsor: European Organisation for Research and Treatment of Cancer - EORTC
N=530 --> 351 N=450 --> 115
- | piperacillin sodium/tazobactam sodium / Generic mfg., vancomycin / Generic mfg.
Enrollment change: Prevention of Infection in Patients With Hematologic Cancer and Persistent Fever Caused by a Low White Blood Cell Count (clinicaltrials.gov) - Sep 19, 2012
P3, N=859, Completed, Sponsor: European Organisation for Research and Treatment of Cancer - EORTC
N=450 --> 115 N=500 --> 859
- Trial completion: Caspofungin Acetate in Treating Aspergillosis in Patients With Hematologic Cancer or in Patients Who Have Undergone a Stem Cell Transplant (clinicaltrials.gov) - Sep 19, 2012
P2, N=171, Completed, Sponsor: European Organisation for Research and Treatment of Cancer - EORTC
N=500 --> 859 Active, not recruiting --> Completed
- | amphotericin b liposome / Generic mfg.
Trial completion: Liposomal Amphotericin B in Treating Granulocytopenia and Persistent Unexplained Fever in Cancer Patients (clinicaltrials.gov) - Sep 19, 2012
P3, N=115, Completed, Sponsor: European Organisation for Research and Treatment of Cancer - EORTC
Active, not recruiting --> Completed Active, not recruiting --> Completed
- | piperacillin sodium/tazobactam sodium / Generic mfg., vancomycin / Generic mfg.
Trial completion: Prevention of Infection in Patients With Hematologic Cancer and Persistent Fever Caused by a Low White Blood Cell Count (clinicaltrials.gov) - Sep 19, 2012
P3, N=859, Completed, Sponsor: European Organisation for Research and Treatment of Cancer - EORTC
Active, not recruiting --> Completed Active, not recruiting --> Completed
- Neupogen (filgrastim) / Kyowa Kirin, Amgen
Trial termination: Donor Stem Cell Transplant Followed By Donor White Blood Cell Infusions in Treating Young Patients With Hematologic Cancer (clinicaltrials.gov) - Sep 11, 2012
P=N/A, N=8, Terminated, Sponsor: University of California, San Francisco
Active, not recruiting --> Completed Completed --> Terminated; lack of efficacy
- Neupogen (filgrastim) / Kyowa Kirin, Amgen
Enrollment change: Donor Stem Cell Transplant Followed By Donor White Blood Cell Infusions in Treating Young Patients With Hematologic Cancer (clinicaltrials.gov) - Sep 11, 2012
P=N/A, N=8, Terminated, Sponsor: University of California, San Francisco
Completed --> Terminated; lack of efficacy N=10 --> 8
- | Monjuvi (tafasitamab-cxix) / Incyte
New P2a trial: Study of Fc-Optimized Anti-CD19 Antibody (MOR00208) to Treat B-cell Acute Lymphoblastic Leukemia(B-ALL) (clinicaltrials.gov) - Sep 11, 2012
P2a, N=30, Recruiting, Sponsor: MorphoSys AG
- Rituxan (rituximab) / Roche
Enrollment closed: Rituximab and Hyper-CVAD (Cyclophosphamide, Vincristine, Adriamycin, and Dexamethasone) for Burkitt's and Burkitt's -Like Leukemia/Lymphoma (clinicaltrials.gov) - Sep 5, 2012
P2, N=70, Active, not recruiting, Sponsor: M.D. Anderson Cancer Center
N=10 --> 8 Recruiting --> Active, not recruiting
- Thymoglobulin (anti-thymocyte globulin (rabbit)) / Sanofi
Trial initiation date: Early Administration of ATG Followed by Cyclophosphamide, Busulfan and Fludarabine Before a Donor Stem Cell Transplant in Patients With Hematological Cancer (clinicaltrials.gov) - Aug 28, 2012
P2, N=24, Completed, Sponsor: Northside Hospital, Inc.
Recruiting --> Active, not recruiting Initiation date: Nov 2006 --> Apr 2007
- Thymoglobulin (anti-thymocyte globulin (rabbit)) / Sanofi
Trial completion: Early Administration of ATG Followed by Cyclophosphamide, Busulfan and Fludarabine Before a Donor Stem Cell Transplant in Patients With Hematological Cancer (clinicaltrials.gov) - Aug 28, 2012
P2, N=24, Completed, Sponsor: Northside Hospital, Inc.
Initiation date: Nov 2006 --> Apr 2007 Active, not recruiting --> Completed
- Beleodaq (belinostat) / Aurobindo, Assertio
Trial completion: PXD101 in Treating Patients With Relapsed or Refractory Aggressive B-Cell Non-Hodgkin's Lymphoma (clinicaltrials.gov) - Aug 19, 2012
P2, N=22, Completed, Sponsor: National Cancer Institute (NCI)
Active, not recruiting --> Completed Active, not recruiting --> Completed
- Rituxan (rituximab) / Roche
Trial withdrawal: Donor T Cells, Low-Dose Aldesleukin, and Low-Dose GM-CSF After Donor Stem Cell Transplant in Treating Patients With Relapsed or Refractory Non-Hodgkin's Lymphoma (clinicaltrials.gov) - Aug 5, 2012
P1, N=0, Withdrawn, Sponsor: Barbara Ann Karmanos Cancer Institute
Active, not recruiting --> Completed Completed --> Withdrawn
- Rituxan (rituximab) / Roche
Enrollment change: Donor T Cells, Low-Dose Aldesleukin, and Low-Dose GM-CSF After Donor Stem Cell Transplant in Treating Patients With Relapsed or Refractory Non-Hodgkin's Lymphoma (clinicaltrials.gov) - Aug 5, 2012
P1, N=0, Withdrawn, Sponsor: Barbara Ann Karmanos Cancer Institute
Completed --> Withdrawn N=30 --> 0
- methoxyamine (TRC102) / Tracon Pharma
New P1 trial: Methoxyamine and Fludarabine Phosphate in Treating Patients With Relapsed or Refractory Hematologic Malignancies (clinicaltrials.gov) - Aug 5, 2012
P1, N=36, Recruiting, Sponsor: Case Comprehensive Cancer Center
- cyclophosphamide / Generic mfg.
Trial completion: Aprepitant, Granisetron, & Dexamethasone in Preventing Nausea & Vomiting in Pts. Receiving Cyclophosphamide Before a Stem Cell Transplant (clinicaltrials.gov) - Aug 5, 2012
P=N/A, N=40, Completed, Sponsor: Barbara Ann Karmanos Cancer Institute
N=30 --> 0 Active, not recruiting --> Completed
- | Enrollment change: Opioid Titration Order Sheet or Standard Care in Treating Patients With Cancer Pain (clinicaltrials.gov) - Aug 3, 2012
P3, N=98, Completed, Sponsor: Vanderbilt-Ingram Cancer Center
Active, not recruiting --> Completed N=128 --> 98
- | Trial completion: Opioid Titration Order Sheet or Standard Care in Treating Patients With Cancer Pain (clinicaltrials.gov) - Aug 3, 2012
P3, N=98, Completed, Sponsor: Vanderbilt-Ingram Cancer Center
N=128 --> 98 Active, not recruiting --> Completed
- Trial completion: COMETH: Coproporphyrine Isomers and Methotrexate Elimination (clinicaltrials.gov) - Jul 29, 2012
P=N/A, N=85, Completed, Sponsor: Assistance Publique - H
Active, not recruiting --> Completed Recruiting --> Completed
- New P2 trial: Single or Double Donor Umbilical Cord Blood Transplant in Treating Patients With High-Risk Hematologic Malignancies (clinicaltrials.gov) - Jul 25, 2012
P2, N=38, Suspended, Sponsor: University of Medicine and Dentistry New Jersey
- Trial withdrawal: Mechanical Stimulation in Preventing Bone Density Loss in Patients Undergoing Donor Stem Cell Transplant (clinicaltrials.gov) - Jul 4, 2012
P=N/A, N=0, Withdrawn, Sponsor: Roswell Park Cancer Institute
Recruiting --> Completed Not yet recruiting --> Withdrawn
- Epratucyn (epratuzumab) / Gilead
Enrollment closed, Combination therapy: S0910 Epratuzumab, Cytarabine, and Clofarabine in Treating Patients With Relapsed or Refractory Acute Lymphoblastic Leukemia (clinicaltrials.gov) - Jul 3, 2012
P2, N=35, Active, not recruiting, Sponsor: Southwest Oncology Group
Not yet recruiting --> Withdrawn Recruiting --> Active, not recruiting
- ||| Clinical: Studying Genes Associated With Non-Hodgkin Lymphoma in Young Patients (clinicaltrials.gov) - Jun 18, 2012
P=N/A, N=483, Active, not recruiting, Sponsor: Children's Oncology Group
- Trial withdrawal: Recombinant Human Mannose-Binding Lectin (MBL) in Treating Young Patients With MBL Deficiency and Fever and Neutropenia (clinicaltrials.gov) - Jun 18, 2012
P1, N=0, Withdrawn, Sponsor: Enzon Pharmaceuticals, Inc.
Recruiting --> Active, not recruiting Recruiting --> Withdrawn
- ||||| Rituxan (rituximab) / Biogen, Zenyaku Kogyo, Roche
Clinical: Combination Chemotherapy With or Without Rituximab in Treating Younger Patients With Stage III-IV Non-Hodgkin Lymphoma or B-Cell Acute Leukemia (clinicaltrials.gov) - Jun 18, 2012
P2/3, N=640, Recruiting, Sponsor: Children's Oncology Group
Recruiting --> Withdrawn Initiation date: Jan 2012 --> Jun 2012
- Enrollment change: Recombinant Human Mannose-Binding Lectin (MBL) in Treating Young Patients With MBL Deficiency and Fever and Neutropenia (clinicaltrials.gov) - Jun 18, 2012
P1, N=0, Withdrawn, Sponsor: Enzon Pharmaceuticals, Inc.
Initiation date: Jan 2012 --> Jun 2012 N=48 --> 0
- |||||| Rituxan (rituximab) / Biogen, Zenyaku Kogyo, Roche
Clinical: Combination Chemotherapy With or Without Rituximab in Treating Younger Patients With Stage III-IV Non-Hodgkin Lymphoma or B-Cell Acute Leukemia (clinicaltrials.gov) - Jun 18, 2012
P2/3, N=640, Recruiting, Sponsor: Children's Oncology Group
N=48 --> 0 Not yet recruiting --> Recruiting
- Zolinza (vorinostat) / Merck (MSD)
Trial withdrawal: COMBOSTAT: Relapsed and/or Refractory Non-Hodgkin Lymphoma Study (clinicaltrials.gov) - Jun 12, 2012
P2, N=0, Withdrawn, Sponsor: The Methodist Hospital System
Not yet recruiting --> Recruiting Not yet recruiting --> Withdrawn
- Zolinza (vorinostat) / Merck (MSD)
Enrollment change: COMBOSTAT: Relapsed and/or Refractory Non-Hodgkin Lymphoma Study (clinicaltrials.gov) - Jun 12, 2012
P2, N=0, Withdrawn, Sponsor: The Methodist Hospital System
Not yet recruiting --> Withdrawn N=95 --> 0
- Trial completion: Irradiated Donor Lymphocyte Infusion in Treating Patients With Relapsed or Refractory Hematologic Cancer or Solid Tumor (clinicaltrials.gov) - Jun 12, 2012
P1, N=37, Completed, Sponsor: University of Medicine and Dentistry New Jersey
N=95 --> 0 Active, not recruiting --> Completed
- Trial termination: Partially HLA-Matched Irradiated Allogeneic Cellular Therapy After Reduced Intensity Total Body Irradiation (clinicaltrials.gov) - Jun 11, 2012
P1, N=4, Terminated, Sponsor: University of Medicine and Dentistry New Jersey
Active, not recruiting --> Completed Recruiting --> Terminated; Slow accrual
- Enrollment change: Partially HLA-Matched Irradiated Allogeneic Cellular Therapy After Reduced Intensity Total Body Irradiation (clinicaltrials.gov) - Jun 11, 2012
P1, N=4, Terminated, Sponsor: University of Medicine and Dentistry New Jersey
Recruiting --> Terminated; Slow accrual N=24 --> 4
- Enrollment closed: Lactobacillus in Preventing Infection in Patients Undergoing a Donor Stem Cell Transplant for Hematologic Cancer or Myelodysplastic Syndrome (clinicaltrials.gov) - Jun 11, 2012
P=N/A, N=30, Active, not recruiting, Sponsor: University of Medicine and Dentistry New Jersey
N=24 --> 4 Recruiting --> Active, not recruiting
- | BI2536 / Boehringer Ingelheim
Trial completion, Metastases: Investigation of Safety, Tolerability and Maximum Tolerated Dose (MTD) of BI 2536 in Patients With Recurrent Advanced Aggressive Non-Hodgkin's Lymphoma (NHL) (clinicaltrials.gov) - Jun 3, 2012
P1, N=41, Completed, Sponsor: Boehringer Ingelheim
Recruiting --> Active, not recruiting Recruiting --> Completed
- Thymoglobulin (anti-thymocyte globulin (rabbit)) / Sanofi
Enrollment closed: Allogeneic Hematopoietic Cell Transplantation for Patients With Busulfex-based Regimen (clinicaltrials.gov) - May 21, 2012
P1/2, N=60, Active, not recruiting, Sponsor: UNC Lineberger Comprehensive Cancer Center
Recruiting --> Completed Completed --> Active, not recruiting
- |||||||||| Rituxan (rituximab) / Biogen, Zenyaku Kogyo, Roche
Clinical: Combination Chemotherapy With or Without Rituximab in Treating Younger Patients With Stage III-IV Non-Hodgkin Lymphoma or B-Cell Acute Leukemia (clinicaltrials.gov) - May 7, 2012
P2/3, N=640, Recruiting, Sponsor: Children's Oncology Group
- ||||| Enrollment change: Effect of Tight Control of Blood Glucose During Hyper-CVAD Chemotherapy For Acute Lymphocytic Leukemia (ALL) (clinicaltrials.gov) - May 6, 2012
P3, N=52, Completed, Sponsor: M.D. Anderson Cancer Center
Completed --> Active, not recruiting N=114 --> 52
- ||||||| Trial completion: Effect of Tight Control of Blood Glucose During Hyper-CVAD Chemotherapy For Acute Lymphocytic Leukemia (ALL) (clinicaltrials.gov) - May 6, 2012
P3, N=52, Completed, Sponsor: M.D. Anderson Cancer Center
N=114 --> 52 Active, not recruiting --> Completed